By targeting CSPG4, we aim to provide preclinical evidence supporting CAR-T-based interventions for DMD-associated cardiomyopathy, offering new insights into potential therapeutic approaches for DMD-related heart failure. This evidence concerns the gene CSPG4 and Duchenne muscular dystrophy.